Department of Pathology, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China.
Department of Urology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China.
Int J Oncol. 2023 Sep;63(3). doi: 10.3892/ijo.2023.5555. Epub 2023 Aug 4.
Clinical efforts on precision medicine are driving the need for accurate diagnostic, new prognostic and novel drug predictive assays to inform patient selection and stratification for disease treatment. Accumulating evidence suggests that a combination of cancer pathology and artificial intelligence (AI) can meet this requirement. In the present review, the past, present and emerging integrations of AI into cancer pathology were comprehensively reviewed, which were divided into four main groups to highlight the roles of AI‑integrated cancer pathology in precision medicine. Furthermore, the unsolved problems and future challenges in AI‑integrated cancer pathology were also discussed. It was found that, although AI‑integrated cancer pathology could enable the amalgamation of complex morphological phenotypes with the multi‑omics datasets that drove precision medicine, synergies of cancer pathology with other medical tools could be more promising for the clinic when making an accurate and rapid decision in personalized treatments for patients. It was hypothesized by the authors that exploring the potential advantages of the multimodal integration of cancer pathology, imaging‑omics, protein‑omics and other‑omics, as well as clinical data to decide upon appropriate management and improve patient outcomes may be the most challenging issue of cancer precision medicine in the future.
临床精准医学的努力推动了对准确诊断、新预后和新型药物预测检测的需求,以告知患者选择和分层进行疾病治疗。越来越多的证据表明,癌症病理学和人工智能 (AI) 的结合可以满足这一要求。在本综述中,全面回顾了 AI 过去、现在和新兴的癌症病理学整合,分为四个主要组,以突出 AI 整合癌症病理学在精准医学中的作用。此外,还讨论了 AI 整合癌症病理学中未解决的问题和未来的挑战。研究发现,尽管 AI 整合癌症病理学可以实现复杂形态表型与推动精准医学的多组学数据集的融合,但在为患者的个性化治疗做出准确快速决策时,癌症病理学与其他医学工具的协同作用可能更有希望应用于临床。作者假设,探索癌症病理学、影像组学、蛋白质组学和其他组学以及临床数据的多模态整合的潜在优势,以决定适当的管理并改善患者预后,可能是未来癌症精准医学最具挑战性的问题。